Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluconazole effect on Sativex PK in healthy subjects
NCT02325011Phase 1Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cannabidiol in multiple sclerosis (MS) (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Pharmacokinetic parameters of Δ9 Tetrahydrocannabinol (THC): Cmax, AUC(0-t) and AUC(0-∞) at 48 hours, Pharmacokinetic parameters of 11-hydroxy-THC (11-OH-THC): Cmax, AUC(0-t) and AUC(0-∞) at 48 hours and 2 more. Started Nov 2014; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02325011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325011.